Next-generation matrix-assisted laser desorption/ionization top-down sequencing (MALDI-TDS) is a highly efficient tool for the characterization of biologics, providing instant information regarding primary sequence, terminal status and near-terminal modifications of protein biotherapeutics.
Next-gen MALDI-TDS analyzes N- and C-terminal MALDI in-source decay (MALDI-ISD) fragments by Trapped Ion Mobility Spectrometry (TIMS) in combination with high-resolution time-of-flight mass spectrometry (TOF-MS).
This webinar will demonstrate the unique capabilities of next-gen MALDI-TDS for in-depth analysis of various pharmaceutical proteins, e.g monoclonal antibodies and viral protein receptor binding domains, and will discuss how the method further expands the biologics toolkit featured by Bruker´s timsTOF fleX ESI/MALDI instrument.
- The benefits of next-gen MALDI-TDS for the characterization of modern biotherapeutics
- The unique contributions of trapped ion mobility to N- and C-terminal sequencing
- The timsTOF fleX biologics toolkit integrating ESI and MALDI workflows
